<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537325</url>
  </required_header>
  <id_info>
    <org_study_id>AKI_TAVI</org_study_id>
    <nct_id>NCT04537325</nct_id>
  </id_info>
  <brief_title>Prevention of Acute Kidney Injury After Transcatheter Aortic Valve Implantation</brief_title>
  <official_title>Prevention of Acute Kidney Injury After Transcatheter Aortic Valve Implantation in Patients With Chronic Kidney Disease With Controlled Intravenous Hydration Matched to Urinary Output</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled, single-center trial randomizing patients with chronic kidney disease&#xD;
      and symptomatic severe aortic valve stenosis undergoing transcatheter aortic valve&#xD;
      implantation (TAVI). Patients are randomized in a 1:1 ratio to periprocedural intravenous&#xD;
      hydration matched to urine output using the RenalGuard system and to standard hydration. The&#xD;
      purpose of the study is to test, wether the controlled intravenous hydration with the&#xD;
      RenalGuard system is superior to standard hydration to prevent acute kidney injury after&#xD;
      TAVI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute kidney injury (AKI) after transcatheter aortic valve implantation (TAVI) is associated&#xD;
      with worse outcome. The RenalGuard system was developed to prevent AKI by a controlled&#xD;
      furosemide-induced diuresis with matched isotonic intravenous hydration. It is based on the&#xD;
      theory, that a high urinary output prevents contrast media-induced nephropathy (CIN).&#xD;
&#xD;
      The present study is a prospective, randomized trial to investigate wether a matched&#xD;
      intravenous hydration using the RenalGuard system is superior to standard pre- and&#xD;
      postprocedural intravenous hydration in patients with severe aortic valve stenosis and&#xD;
      chronic kidney disease undergoing TAVI. Primary endpoint is the occurrence of AKI after TAVI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 20, 2017</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">August 16, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>Within 7 days after Transcatheter aortic valve implantation</time_frame>
    <description>Increase of serum-creatinine of 0,3 mg/dl in pre-procedural serum-creatinine within 7 days after Transcatheter aortic valve implantation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>RenalGuard group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RenalGuard system</intervention_name>
    <description>Periprocedural intravenous hydration matched to urinary output.</description>
    <arm_group_label>RenalGuard group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic severe aortic valve stenosis undergoing transcatheter aortic valve&#xD;
             implantation&#xD;
&#xD;
          -  Chronic kidney disease (baseline glomerular filtration rate ≤ 60 ml/min)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
&#xD;
          -  Dialysis-dependent chronic kidney injury&#xD;
&#xD;
          -  Emergency transcatheter aortic valve stenosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Schäfer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 29, 2020</study_first_submitted>
  <study_first_submitted_qc>August 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter aortic valve stenosis</keyword>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Acute kidney injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

